Better Buy: Gilead Sciences, Inc. vs. Pfizer
The biopharmaceutical industry has been exceptionally kind to investors over the past six years because of the introduction of several new classes of drugs, greater insurance coverage for low-income individuals in the United States, and the aging global population. Even so, the industry's best days are likely still ahead, thanks to these very same growth drivers.
Although the biopharmaceutical giants Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE) are both well positioned to take advantage of this favorable growth trend, one stock clearly stands out as the far more attractive buy right now. Read on to find out which of these top pharma stocks this Fool favors as a long-term buy and hold.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Stock
€25.73
-0.140%
Currently there is a rather positive sentiment for Pfizer Inc. with 27 Buy predictions and 5 Sell predictions.
With a target price of 40 € there is a hugely positive potential of 55.49% for Pfizer Inc. compared to the current price of 25.73 €.
